Restriction of SARS-CoV-2 Replication by Targeting Programmed -1 Ribosomal Frameshifting In Vitro
Yu Sun, Laura Abriola, Rachel O. Niederer, Savannah F. Steinhauser, Mia Madel Alfajaro, Valter Silva Monteiro, Craig B. Wilen, Ya‐Chi Ho, Wendy V. Gilbert, Yulia V. Surovtseva, Brett D. Lindenbach, Junjie U. Guo
This study identifies merafloxacin as a -1 PRF inhibitor that impedes SARS-CoV-2 replication in vitro.
Proceedings of the National Academy of Sciences · Jun 14, 2021Peer-reviewedMolecular Biology